A General Evaluation on Current Global Threat of Coronavirus (Covid-19) Immuno Responsibilities

Öz

Covid-19 SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) is a new type of coronavirus known as an infectious upper respiratory tract infection disease. The coronavirus, which poses a great threat to human health worldwide, emerged in Wuhan, China in December 2019. The most important reason for coronavirus epidemics to become a pandemic that the disease was easily transmitted by droplets in close proximity with infected people. The disease spread rapidly all over the world within a few months and it was declared a worldwide epidemic by the World Health Organization in March 2020. It poses a risk for severe diseases such as hypertension, diabetes, cardiovascular disease, cancer, chronic lung disease and chronic kidney disease in the advanced age group. Considering the mortality rates to date, great efforts have been made both worldwide and in our country to manifacture successful drugs and vaccines against Covid-19 infection. The main purpose of this review is to assist in an immune response and preventive work for Covid-19, thanks to the available information about the coronavirus epidemic that deeply affects humanity and the diseases it causes.

Anahtar Kelimeler

• ACE2 reseptor
• Coronavirus
• Covid-19
• Spike protein
• Treatment vaccine

Mevcut Küresel Koronavirüs Tehdidinin (Covid-19) İmmün Sorumlulukları Hakkında Genel Bir Değerlendirme

Öz

Covid-19 SARS-CoV-2 (şiddetli akut solunum sendromu-koronavirüs-2), bulaşıcı bir üst solunum yolu enfeksiyonu hastalığı olarak bilinen yeni bir koronavirüs türüdür. Dünya genelinde insan sağlığı için büyük bir tehdit oluşturan koronavirüs, Aralık 2019'da Çin'in Wuhan kentinde ortaya çıkmıştır. Koronavirüs salgınlarının pandemi haline gelmesinin en önemli nedeni, hastalığın enfekte kişilerin yakınında bulunan damlacıklar yoluyla kolayca bulaşmasıdır. Birkaç ay içinde hızla tüm dünyaya yayılan hastalık, Mart 2020'de Dünya Sağlık Örgütü tarafından dünya çapında bir salgın olarak ilan edilmiştir. İleri yaş grubunda hipertansiyon, diyabet, kardiyovasküler hastalık, kanser, kronik akciğer hastalığı ve kronik böbrek hastalığı gibi ağır hastalık tablosu için risk oluşturmaktadır. Bugüne kadar ölüm oranları göz önüne alındığında, Covid-19 enfeksiyonuna karşı başarılı ilaçlar ve aşılar üretmek için hem dünya çapında hem de ülkemizde büyük çabalar sarf edilmektedir. Bu derlemenin temel amacı, insanlığı derinden etkileyen koronavirüs salgını ve neden olduğu hastalıklar hakkında elde edilen mevcut bilgiler sayesinde Covid-19 için bir bağışıklık müdahalesine ve önleyici çalışmalara yardımcı olmaktır.

Anahtar Kelimeler

• Covid-19
• ACE2 reseptörü
• Coronavirüs
• Spike proteini
• Aşı tedavisi

Kaynakça

1. [1] Yucel B., Gormez A. SARS- corona virus overview. Turk Journal Applied Science Technology 2019; 2(1): 32-39.
2. [2] Akpınar F., Ustun Y. Current information about SARS-COV-2 (Covid-19) infection in obstetrics and gynecology practice. Turk Journal of Womens Health Neonatology 2020; 2(1): 13-16.
3. [3] Buruk K., Ozlu T. New coronavirus: SARS-CoV-2. Mucosa 2020; 3(1): 1-4.
4. [4] Alimoglu O., Erol C.I. Approach to general surgery practice during Covid-19 pandemic. Anatolian Clinic Journal of Medical Sciences 2020; 25(1): 102-110.
5. [5] Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E.A. Comprehensive review of Covid-19 characteristics. Biologic Procedure 2020; 22: 1-10.
6. [6] Alkan Cevıker S., Dindar Demiray E.K. Other respiratory viruses for di¬ erential diagnosis of SARS-CoV-2 (Covid-19) infection. Journal Biotechnology and Strategic Health Research 2020; 1: 45-49.
7. [7] Inal Ince D., Vardar Yağlı N., Saglam M., Kutukcu E. Acute and postacut physiotherapy and rehabilitation in Covid-19 infection. Turk Journal of Physiotherapy Rehabilitation 2020; 31(1): 81-93.
8. [8] Ors I. Covid-19 and skin. Konya Karatay University Journal of Health Sciences 2020; 3: 26-29.

9. [9] Ugras Dikmen A., Kına H.M., Ozkan S., Ilhan M.N. Epidemiology of Covid-19: What we learn from pandemic. Journal of Biotechnology and Strategic Health Research 2020; 1: 29-36.
10. [10] Yılmaz D. Infection in terms of dentistry and dental clinics. Journal of Biotechnology and Strategic Health Research 2020; 1: 22-28.
11. [11] Su S., Wong G., Shi W., Liu J., Lai A.C., Zhou J., Liu W., Bi Y., Gao G.F. Epidemiology, genetic recombination and pathogenesis of coronaviruses. Trends in Microbiology 2016; 24(6): 490-502.
12. [12] Shi Y., Wang G., Cai X.P., Deng J.W., Zheng L., Zhu H.H., Zheng M., Yang B., Chen Z. An overview of Covid-19. Zhejiang Univ-Sci B (Biomedical & Biotechnology) 2020; 21(5): 343-360.
13. [13] Sohrabi C., Alsafib Z., O'Neilla N., Khanb M., Kerwanc A., Al-Jabir A., Iosifidis C., Agha R. World health organization declares global emergency: A review of the 2019 novel coronavirus (Covid-19). International Journal of Surgery 2020; 76: 71-76.
14. [14] Tanriverdi ES., Yakupogulları Y., Otlu B. Features of Covid-19 Agent. Turkey Clinical Microbiology 2020; 7-14.
15. [15] Kurtulus M., Pırım I. Covid-19 and cytokine storm. Forbes Journal of Medicine 2020; 1(3): 55-60.
16. [16] https://covid19.saglik.gov.tr/ (Accessed 08.05.2021).
17. [17] Akboga O. New Type coronavirus (Covid-19) outbreak. Ordu University Journal of Nursing Studies 2020; 3(2): 153-162.
18. [18] Uludag O. Coronavirus infections and new enemy: Covid-19. Adıyaman University Journal of Health Sciences 2020; 6(1): 118-127.
19. [19] Baloch S., Baloch M.A., Zheng T., Pei X. The coronavirus disease 2019 (Covid-19) pandemic. The Tohoku Journal of Experimental Medicine 2020; 250(4): 271-278.
20. [20] Bernheim A., Mei X., Huang M., Yang Y., Fayad Z.A., Zhang N., Diao K., Lin B., Zhu X., Li K., Li S., Shan H., Jacobi A., Chung M. Chest CT findings in coronavirus disease-19 (Covid-19): Relationship to duration of infection. RSNA Radiology 2020; 295(3): 685-691.
21. [21] Zhu N., Zhang D., Wang W., Yang Y., Fayad Z.A., Zhang N., Diao K., Lin B., Zhu X., Li K., Li S., Shan H., Jacobi A., Chung M.A. Novel coronavirus from patients with pneumonia in china. New England Journal of Medicine 2020; 382(8): 727-733.
22. [22] Samancı M.A. Global outbreak: Covid-19. Journal of Samsun Health Sciences 2020; 5(1): 6-11.
23. [23] Dai J., Gu L., Su Y., Wang Q., Zhao Y., Chen X., Deng H., Li W., Wang G., Li K. Inhibition of Curcumin on influenza a virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. International Immunopharmacology 2018; 54: 177-187.
24. [24] Aslan A., Hussein Y.T., Gok O., Beyaz S., Erman O., Baspinar S. Ellagic acid ameliorates lung damage in rats via modulating antioxidant activities, inhibitory effects on inflammatory mediators and apoptosis-inducing activities. Enviromental Science and Pollution Research 2020a; 27(7): 7526-7537.
25. [25] Aslan A., Beyaz S., Gok O., Erman O. The effect of ellagic acid on Caspase-3/bcl-2/Nrf-2/NF-κB/TNF-α/COX-2 gene expression product apoptosis pathway: A new approach for muscle damage therapy. Molecular Biology Reports 2020b; 47(4): 2573–2582.
26. [26] https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (Accessed 08.05.2021).